



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/252138/2014

European Medicines Agency decision

P/0128/2014

of 22 May 2014

on the acceptance of a modification of an agreed paediatric investigation plan for abatacept (Orencia) (EMA-000118-PIP02-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0128/2014

of 22 May 2014

on the acceptance of a modification of an agreed paediatric investigation plan for abatacept (Orencia) (EMA-000118-PIP02-10-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/64/2011 issued on 10 March 2011, and the decision P/0133/2012 issued on 2 July 2012,

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 3 February 2014 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 25 April 2014, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for abatacept (Orencia), solution for injection, subcutaneous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This agreed PIP covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/87/2008 issued on 14 October 2008 including subsequent modifications thereof.

Article 3

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, UB8 1DH – Uxbridge, United Kingdom.

Done at London, 22 May 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/73694/2014

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000118-PIP02-10-M02

Scope of the application

Active substance(s):

Abatacept

Invented name:

Orencia

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name / corporate name of the PIP applicant:

Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 3 February 2014 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/64/2011 issued on 10 March 2011, and the decision P/0133/2012 issued on 2 July 2012.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 26 February 2014.

Scope of the modification

Some measures and/or timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report :

- to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 25 April 2014

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

The waiver applies to:

- children from birth to less than 2 years;
- for solution for injection, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition: treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of moderate to severe polyarticular juvenile idiopathic arthritis.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

For measures in this condition that are not specified in the table below, reference is made to PIP no. EMEA-000118-PIP01-07 that has been agreed pursuant to EMA decision no. P/87/2008 dated 14 October 2008 including any subsequent modifications. Compliance check for these measures has been performed as per PDCO opinion no. EMEA/PDCO/329594/2009 (EMEA-C-000118-PIP01-07-M01).

Area	Number of studies	Description
Quality-related studies	1	Study 1 Development of solution for injection in pre-filled syringes (0.4 and 0.7 ml) for paediatric use
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 3 Open-label study to evaluate pharmacokinetics, treatment response and safety of abatacept administered subcutaneously in patients with juvenile idiopathic arthritis
Extrapolation, modelling and simulation studies	1	Study 2 Pharmacokinetic modelling and simulation study
Other studies	0	N.A.
Other measures	0	N.A.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By October 2019
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of rheumatoid arthritis

Authorised indication(s):

- ORENCIA in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.

2. Treatment of juvenile idiopathic arthritis

Authorised indication(s):

- ORENCIA in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (JIA) in paediatric patients 6 years of age and older who have had an insufficient response to other DMARDs including at least one TNF inhibitor.

Authorised pharmaceutical form(s):

Powder for concentrate for solution for infusion.

Authorised route(s) of administration:

Intravenous use.